Drugs

HTA ID	Drug	Brand	Indication	Assessment status	Date
-	Ixazomib	Ninlaro®	In combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.	Assessment process complete	18th December 2017
-	Ixekizumab	Taltz®	For the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.	Rapid Review Complete	26th July 2016
-	Ixekizumab	Taltz®	For the treatment of active PsA in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drug (DMARD) therapies	Rapid Review Complete	20th November 2018
21046	Ketoconazole	Ketoconazole HRA®	For the treatment of endogenous Cushing’s syndrome in adults and adolescents above the age of 12 years.	Rapid Review Complete	13th December 2021
-	Lacosamide	Vimpat®	As monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.  The Applicant is seeking reimbursement for an extension to the product license to cover children (≥4 years of age) and adolescents (≤ 15 years of age).	Rapid Review Complete	31st October 2017
__	Lanadelumab	Takhzyro®	For routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older.	Assessment process complete	26th June 2020
-	Lapatinib	Tyverb®	For the treatment of women with previously treated advanced or metastatic HER2 positive breast cancer.	Assessment process complete	28th January 2008
19050	Larotrectinib	Vitrakvi®	For patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion.	Assessment process complete	23rd November 2021
21053	Latanoprost/Timolol	Fixapost®	In adults (including the elderly) for the reduction of intraocular pressure in patients with open angle glaucoma and ocular hypertension who are insufficiently responsive to topical beta‐blockers or prostaglandin analogues.	Rapid Review Complete	6th December 2021
-	Ledipasvir/sofosbuvir	Harvoni®	For the treatment of Chronic Hepatitis C (CHC) infection (Genotye 1, 3 and 4)  in adults.	Assessment process complete	20th November 2015
-	Lenalidomide	Revlimid®	For the treatment of adult patients with previously untreated multiple myelomas (MM) who are not eligible for transplant (licence extension).	Rapid Review Complete	20th November 2015
-	Lenvatinib	Kisplyx®	In combination with everolimus for the treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior vascular endothelial growth factor (VEGF)-targeted therapy.	Rapid Review Complete	18th May 2017
22057	Lenvatinib	Kisplyx®	For the treatment of adults with advanced renal cell carcinoma, in combination with pembrolizumab, as first-line treatment	Rapid Review Complete	22nd September 2022
-	Lenvatinib	Lenvima®	For the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine.	Rapid Review Complete	10th July 2015
-	Lenvatinib	Lenvima®	As monotherapy for the treatment of adult patients with advanced or unresectable HCC who have received no prior systemic therapy.	Rapid Review Complete	16th August 2018
-	Lesinurad	Zurampic®	For the treatment of hyperuricaemia in adult patients with gout who have not achieved target serum uric acid levels with an adequate dose of a xanthine oxidase inhibitor.	Assessment process complete	6th December 2018
-	Letermovir	Prevymis®	For the prophylaxis of cytomegalovirus (CMV) reactivation or disease in adult CMV-seropositive recipients [R+] of an allogeneic haematopoietic stem cell transplant (HSCT).	Assessment process complete	20th May 2020
-	Levodopa 20mg/ml + carbidopa monohydrate 5mg intestinal gel	Duodopa®	For the treatment of advanced levodopa-responsive Parkinson’s disease with severe motor fluctuations and hyper-/dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results. A positive test of the clinical response to Duodopa® administered via a temporary nasoduodenal tube is required before a permanent tube is inserted.	Assessment process complete	14th June 2019
21068	Levodopa/carbidopa/entacapone intestinal gel	Lecigon®	For the treatment of advanced Parkinson's disease with severe motor fluctuations and hyperkinesia or dyskinesia when available oral combinations of Parkinson’s medicinal products have not given satisfactory results.	Rapid Review Complete	17th February 2022
-	Levofloxacin	Quinsair®	For the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with Cystic Fibrosis.	Rapid Review Complete	2nd March 2016
-	Levonorgestrel intrauterine delivery system LNG IUS 12	Kyleena®	For contraception for up to 5 years.	Rapid Review Complete	16th March 2017
-	Levonorgestrel Intrauterine System	Levosert®	For contraception and for the treatment of heavy menstrual bleeding.	Rapid Review Complete	23rd October 2019
-	Levonorgestrel intrauterine system LNG-IUS	Jaydess®	For contraception for up to three years.	Rapid Review Complete	26th March 2013
-	Lidocaine 5% plasters	Versatis®	For the symptomatic relief of neuropathic pain associated with previous herpes zoster infection (post-herpetic neuralgia, PHN).	Assessment process complete	24th September 2015
-	Linaclotide	Constella®	For the treatment of symptomatic treatment of moderate to severe irritable bowel syndrome with constipation (IBS-C) in adults.	Rapid Review Complete	28th June 2013
-	Linagliptin	Trajenta®	For treatment of type 2 diabetes mellitus to improve glycaemic control in adults, as monotherapy in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to intolerance, or contraindicated due to renal impairment, as combination therapy in combination with metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control, in combination with a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.	Rapid Review Complete	6th September 2011
-	Lipegfilgrastim	Lonquex®	For reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).	Rapid Review Complete	24th September 2013
-	Liposomal daunorubicin and cytarabine	Vyxeos Liposomal®	For the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes.	Assessment process complete	16th April 2020
-	Liquid Paraffin Ointment	VitA-POS Opthalmic®	For the treatment of mild to moderate form of dry eye.	Rapid Review Complete	31st January 2014
19039	Liraglutide	Saxenda®	As an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial body mass index (BMI) of ≥30kg/m2 (obese), or ≥27kg/m2 to <30kg/m2 (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea. The Applicant is seeking reimbursement in a subgroup of the licensed population, that is,  as an adjunct to a reduced calorie diet and increased physical activity for weight management in adult patients with an initial body mass index of ≥35kg/m2 with pre-diabetes and high risk of cardiovascular disease.	Assessment process complete	10th February 2021
-	Liraglutide	Victoza®	For treatment of adults with type 2 diabetes mellitus.	Assessment process complete	7th March 2019
-	Lisdexamfetamine dimesylate	Tyvense®	For Attention Deficit Hyperactivity Disorder in children aged 6 years and over when response to previous methylphenidate treatment is considered clinically inadequate.	Rapid Review Complete	28th February 2013
__	__	__	__	__	7th August 2014
-	Lomitapide	Lojuxta®	As an adjunct to a low-fat diet and other lipid-lowering medicinal products with or without low density lipoprotein (LDL) apheresis in adult patients with homozygous familial hypercholesterolaemia (HoFH).	Rapid Review Complete	15th September 2014
-	Lorlatinib	Lorviqua®	As monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), following disease progression on: (i) alectinib or ceritinib as the first ALK-targeted treatment, or (ii) crizotinib and at least one other ALK-targeted treatment.	Rapid Review Complete	25th June 2019
21071	Lorlatinib	Lorviqua®	As monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.	Rapid Review Complete	13th January 2022
-	Lornoxicam	Xefo®	For the short-term relief of acute mild to moderate pain and symptomatic relief of pain and inflammation in osteoarthritis and symptomatic relief of pain and inflammation in rheumatoid arthritis	Rapid Review Complete	7th July 2011
-	Loteprednol	Lotemax 0.5% eye drops suspension	For treatment of post-operative inflammation following ocular surgery.	Rapid Review Complete	5th December 2011
-	Loxapine inhalation powder	Adasuve®	For the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder.	Rapid Review Complete	28th July 2016
-	Lumacaftor/ivacaftor	Orkambi®	For the treatment of cystic fibrosis (CF) in patients aged 12 years and older who are homozygous for the F508del mutation in the CFTR gene.	Assessment process complete	1st June 2016
-	Lutetium (177Lu) Oxodotreotide	Lutathera®	For the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor (SSTR) positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults.	Assessment process complete	11th February 2020
23002	Lutetium (177Lu) vipivotide tetraxetan	Pluvicto®	__	Awaiting full HTA submission from Applicant	10th February 2023
22062	Macimorelin acetate	Ghryvelin®	For the diagnosis of growth hormone deficiency (GHD) in adults.	Rapid Review Complete	4th October 2022
-	Macitentan	Opsumit®	Macitentan is indicated as monotherapy or in combination, for the long term treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III.	Rapid Review Complete	31st January 2014
-	Magnesium Aspartate Dihydrate	Magnaspartate®	For the treatment and prevention of magnesium deficiency as diagnosed by a doctor. Magnaspartate is indicated in adults, children and adolescents aged from 2 years.	Rapid Review Complete	14th May 2019
-	Mannitol Dry Powder	Bronchitol®	Mannitol dry powder for inhalation for the treatment of cystic fibrosis (CF)	Assessment Process Complete	29th April 2019
22069	Maribavir	Livtencity®	For the treatment of cytomegalovirus (CMV) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant or solid organ transplant.	Rapid Review Complete	13th December 2022
-	Melatonin	Circadin®	Prolonged release melatonin (Circadin®) for the short-term treatment of primary insomnia.	Full HTA Assessment	21st October 2008
22048	Melatonin	Slenyto®	For the treatment of insomnia in children and adolescents aged 2-18 with Autism Spectrum Disorder (ASD) and / or Smith-Magenis syndrome (SMS), where sleep hygiene measures have been insufficient.	Rapid Review Complete	9th August 2022
-	Mepolizumab	Nucala®	Is indicated as an add-on treatment for severe refractory eosinophilic asthma in adult patients.	Assessment Process Complete	1st March 2017